LS174T-luc Orthotopic Mouse Model Service for Colon Cancer

The LS174T-luc orthotopic mouse model offers a mucin-secreting, CMS1-classified human colorectal adenocarcinoma platform distinguished by exceptionally high MUC2 production and dense extracellular matrix deposition, enabling evaluation of mucin-targeted therapies, drug penetration enhancers, and combination regimens within a physiologically faithful colonic microenvironment. Alfa Cytology constructs and manages this orthotopic xenograft platform with authenticated luciferase-expressing cell stocks, standardized cecal wall implantation protocols, and integrated IVIS bioluminescence imaging infrastructure, delivering quantitative in vivo datasets that capture mucin-rich tumor growth dynamics, treatment-induced regression, and barrier-modulation effects with temporal resolution essential for advancing mucinous colorectal cancer drug development.

Overview of LS174T-luc Orthotopic Mouse Model for Colon Cancer

The LS174T cell line is a human colorectal adenocarcinoma originally established as a trypsin-adapted variant of LS180 from a 58-year-old Caucasian female patient diagnosed with Dukes' type B (Stage II) colorectal adenocarcinoma. Genetically, LS174T is classified within the consensus molecular subtype 1 (CMS1), characterized by microsatellite instability and immune activation, though the line also exhibits features of the mucinous phenotype. The line harbors an activating KRAS mutation at codon 12 (G12D, p.Gly12Asp) that drives constitutive MAPK/ERK signaling, alongside inactivating alterations in TP53 and APC that compromise DNA damage responses and dysregulate canonical Wnt/^β-catenin signaling, respectively. An additional PIK3CA activating mutation (H1047R) further potentiates survival signaling through the PI3K/AKT/mTOR axis. The near-diploid karyotype with a modal chromosome number of 45,X reflects a relatively stable genomic architecture compared to hyper-diploid counterparts. The luciferase-transduced derivative (LS174T-luc) was generated by stable integration of firefly (Photinus pyralis) luciferase via lentiviral transduction under constitutive promoter control, with puromycin selection ensuring sustained reporter expression across passages.

Fig 1. (Left) NIRF images acquired 24, 72, and 120 h after the administration of RA96-IR800 (50 μg in 100 μL 0.9% sterile saline) to a mouse bearing a subcutaneous LS174T xenograft. (Right) Ex vivo image of the tumor and organs of interest acquired immediately after the 120 h in vivo imaging time point. (Grimaldi, Camilla, et al., 2026)

A defining biological hallmark of LS174T is its exceptional mucin secretory capacity: the line expresses the highest levels of MUC2 mRNA among commonly used colorectal cancer cell lines, producing abundant intracytoplasmic mucin vacuoles and secreting large quantities of carcinoembryonic antigen (CEA), interleukin-6 (IL-6), and interleukin-10 (IL-10). This mucin-rich phenotype generates a dense extracellular matrix that restricts antibody penetration, limits immune cell infiltration, and creates a formidable pharmacokinetic barrier—mimicking the therapeutic challenges of mucinous colorectal carcinoma in the clinic. Orthotopic implantation of LS174T-luc cells into the cecal wall of immunodeficient mice reconstructs the native colonic stromal architecture, with bioluminescence signals detectable within 7–10 days and tumors progressing to endpoint volumes over 4–6 weeks. The model has been extensively employed to evaluate mucin-targeted therapies, assess antibody distribution barriers, investigate rapamycin resistance mediated through JNK pathway activation, and validate anti-angiogenic strategies, making it an indispensable platform for preclinical development in mucinous and KRAS-mutant colorectal malignancies.

Cell Line Information: LS174T-luc

The LS174T-luc cell line merges the mucin-secreting, CMS1-classified colorectal adenocarcinoma phenotype of the parental LS174T line with a stably integrated firefly luciferase reporter cassette, enabling quantitative optical readouts of tumor burden in a mucin-dense microenvironment. The table below consolidates its essential biological, genetic, reporter, and culture parameters:

Our Services

Alfa Cytology delivers a comprehensive LS174T-luc orthotopic model service encompassing authenticated luciferase-expressing cell line banking, surgical cecal wall implantation in immunodeficient hosts, serial bioluminescence imaging, therapeutic intervention, mucin barrier assessment, and multi-parameter endpoint analysis. Our platform is uniquely optimized for mucinous colorectal cancer studies, leveraging the line's exceptional MUC2 secretory capacity and dense extracellular matrix to generate datasets that inform mucin-targeted therapy, drug penetration enhancement, and barrier-modulation strategies.

Workflow of LS174T-luc Orthotopic Mouse Model Construction

Establishment of the LS174T-luc orthotopic model requires coordinated execution of luciferase validation, sterile surgical technique, and calibrated bioluminescence imaging to achieve consistent engraftment in a mucin-dense tumor microenvironment. The protocol proceeds through the following sequential stages:

1. Cell Expansion and Luciferase Validation: LS174T-luc cells are propagated under puromycin selection to maintain luciferase expression, authenticated via STR profiling against the human reference, and confirmed mycoplasma-negative. Luciferase activity is quantified in vitro using a D-luciferin luminometric assay to verify reporter functionality and establish baseline photon flux per cell prior to in vivo use. Cells are harvested during logarithmic growth, counted, and resuspended in ice-cold PBS.
2. Recipient Mouse Preparation: Female athymic nude (BALB/c nu/nu) or NOD-scid mice (6–8 weeks old) are quarantined and acclimated for a minimum of 72 hours. Health status is assessed daily, and any mice displaying abnormal behavior or weight loss are excluded prior to cell implantation.
3. Matrigel Suspension Preparation: The cell suspension is mixed 1:1 by volume with ice-cold Matrigel Basement Membrane Matrix immediately prior to injection. Matrigel provides an extracellular scaffold that supports initial tumor colonization within the cecal wall and facilitates mucin matrix deposition characteristic of the LS174T phenotype.
4. Surgical Cecal Wall Implantation: Under general anesthesia, a midline laparotomy (~10 mm) is performed, and the cecum is exteriorized onto sterile gauze moistened with PBS. A small cecotomy is made at the cecal tip, and 50–100 µL of the Matrigel-cell suspension (5 × 10⁵ to 1 × 10⁶ cells) is injected submucosally into the cecal wall from the luminal side using a 27-gauge needle. The cecotomy is closed with interrupted 5-0 silk sutures in Lembert fashion, the cecum is returned to the abdominal cavity, and the abdominal wall is closed in two layers.
5. Postoperative Care and Monitoring: Mice receive sustained-release buprenorphine for analgesia and are monitored closely during the 48-hour perioperative period for signs of pain, dehydration, or intestinal obstruction. Body weights are recorded daily for the first week and twice weekly thereafter.
6. Baseline Bioluminescence Imaging and Cohort Stratification: At 7–10 days post-implantation, mice receive intraperitoneal D-luciferin (150 mg/kg) and are imaged under isoflurane anesthesia using an IVIS spectrum system. Tumor-bearing mice with detectable bioluminescent signals are stratified by photon flux intensity into homogeneous treatment cohorts, ensuring balanced baseline signal distributions. Mice without detectable signal by day 14 are excluded from analysis.
7. Therapeutic Intervention and Serial Bioluminescence Monitoring: Test compounds are administered according to the predefined regimen. Bioluminescence imaging is performed at regular intervals (typically weekly) to quantify tumor growth dynamics, treatment-induced signal attenuation, and potential regrowth. Photon flux values are normalized to baseline and plotted as normalized total flux over time. Body weights and clinical signs are recorded concurrently.
8. Endpoint Necropsy, Ex Vivo Imaging, and Comprehensive Analysis: Upon reaching study endpoints (tumor volume ~1,500–2,000 mm³, humane moribund criteria, or scheduled termination), mice are euthanized. The primary cecal tumor is excised, weighed, and photographed. Ex vivo bioluminescence imaging confirms in vivo imaging accuracy. Tumor tissues are fixed for H&E and immunohistochemistry (MUC2, MUC5AC, CEA, CD31, Ki-67, cleaved caspase-3, phospho-ERK), or snap-frozen for Western blot, qPCR, and RNA-seq. Mucin content is quantified by Alcian Blue staining.

Fig 2. LS174T-luc orthotopic mouse model construction workflow.

Case Study-LS174T-luc Orthotopic Mouse Model Development

In a preclinical program investigating mucin barrier modulation in KRAS-mutant colorectal cancer, the LS174T-luc orthotopic model was employed to evaluate the efficacy of a novel mucolytic agent administered in combination with an anti-EGFR antibody. Following surgical cecal wall implantation and baseline bioluminescence imaging stratification, treatment cohorts received the mucolytic agent alone, the anti-EGFR antibody alone, the combination regimen, or vehicle control. Serial bioluminescence imaging revealed that the anti-EGFR monotherapy produced only modest signal attenuation, consistent with the documented mucin-mediated antibody penetration barrier characteristic of LS174T tumors. In contrast, the combination cohort exhibited rapid and sustained photon flux reduction within the first two weeks, with significantly diminished tumor signal intensity maintained throughout the study duration. Endpoint histopathological analysis demonstrated markedly reduced MUC2 and MUC5AC staining in the combination-treated tumors, alongside increased anti-EGFR antibody penetration depth into the tumor parenchyma as visualized by immunofluorescence. Reduced Ki-67 proliferation indices and enhanced cleaved caspase-3 staining were observed in the combination group, correlating with improved drug distribution. These findings illustrate the model's unique capacity to evaluate mucin-targeted barrier-modulation strategies and their impact on therapeutic antibody penetration, providing actionable insights for optimizing drug delivery in mucinous colorectal malignancies.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your LS174T-luc orthotopic colon cancer study provides access to a specialized platform that bridges mucinous tumor biology with quantitative bioluminescence imaging and barrier-modulation assessment. Our distinguishing capabilities include:

• Authenticated LS174T-luc cell banking with documented STR profiling, mycoplasma clearance, and passage-controlled expansion to preserve MUC2 secretory capacity, KRAS G12D mutation fidelity, and luciferase reporter integrity across study cohorts.
• In-house IVIS bioluminescence imaging infrastructure enabling quantitative, non-invasive tumor tracking with normalized photon flux analysis, capturing mucin-rich tumor growth kinetics, treatment response, and regrowth patterns in real time.
• Skilled surgical team experienced in cecal wall orthotopic implantation with consistent engraftment rates and low perioperative mortality, ensuring robust statistical power for mucinous tumor endpoint analysis.
• Integrated mucin barrier assessment capabilities encompassing Alcian Blue and PAS staining for mucin quantification, MUC2/MUC5AC immunohistochemistry, and antibody penetration depth analysis by immunofluorescence microscopy.
• Flexible combination study designs supporting mucolytic agents, mucin-targeted therapies, anti-EGFR antibodies, mTOR/JNK pathway inhibitors, and drug penetration enhancers with customized dosing schedules and barrier-modulation endpoints.
• Dedicated project scientists providing weekly bioluminescence data updates, interim mucin content assessments, and collaborative interpretation of barrier-modulation effects on therapeutic efficacy to align preclinical outcomes with your mucinous colorectal cancer development roadmap.

Contact Us

If your preclinical program demands a mucin-secreting colorectal cancer model that faithfully recapitulates the in vivo mucin barrier and dense extracellular matrix of mucinous colorectal carcinoma, we invite you to reach out to us to discuss how Alfa Cytology can design and execute a tailored LS174T-luc orthotopic study aligned with your mucin-targeted therapeutic hypotheses. From surgical implantation and serial bioluminescence imaging through mucin barrier assessment and comprehensive endpoint profiling, our team is committed to delivering mechanistically rich data that advance your mucinous colorectal cancer drug development program. Contact us today to initiate your project and leverage our integrated bioluminescence imaging platform for your next-generation mucin-modulation candidate.

For research use only. Not intended for any clinical use.